Alto Neuroscience, Inc. Operating Income
Alto Neuroscience, Inc. (ANRO) reported Operating Income of -$29.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Alto Neuroscience, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$29.13M.
- Alto Neuroscience, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$27.14M.
- Alto Neuroscience, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$17.05M.
- Alto Neuroscience, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$14.95M.
- Alto Neuroscience, Inc. operating income (loss) for fiscal 2025 was -$66.36M.
- Alto Neuroscience, Inc. operating income (loss) for fiscal 2024 was -$68.61M.
- Alto Neuroscience, Inc. operating income (loss) for fiscal 2023 was -$37.81M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$29.13M 10-Q · filed 2026-08-12 | -$56.27M 10-Q · filed 2026-08-12 | -$73.32M derived: sum of 3 quarters · filed 2026-08-12 | -$88.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$27.14M 10-Q · filed 2026-05-13 | -$44.19M derived: sum of 2 quarters · filed 2026-05-13 | -$59.14M derived: sum of 3 quarters · filed 2026-05-13 | -$77.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$17.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$32.01M derived: sum of 2 quarters · filed 2026-03-16 | -$50.69M derived: sum of 3 quarters · filed 2026-08-12 | -$66.36M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$14.95M 10-Q · filed 2025-11-12 | -$33.63M derived: sum of 2 quarters · filed 2026-08-12 | -$49.31M 10-Q · filed 2025-11-12 | -$66.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$18.68M 10-Q · filed 2026-08-12 | -$34.36M 10-Q · filed 2026-08-12 | -$51.35M derived: sum of 3 quarters · filed 2026-08-12 | -$70.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$15.68M 10-Q · filed 2026-05-13 | -$32.67M derived: sum of 2 quarters · filed 2026-05-13 | -$51.56M derived: sum of 3 quarters · filed 2026-05-13 | -$69.90M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$35.88M derived: sum of 2 quarters · filed 2026-03-16 | -$54.22M derived: sum of 3 quarters · filed 2026-03-16 | -$68.61M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$18.89M 10-Q · filed 2025-11-12 | -$37.23M derived: sum of 2 quarters · filed 2025-11-12 | -$51.61M 10-Q · filed 2025-11-12 | -$63.38M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$18.34M 10-Q · filed 2025-08-13 | -$32.73M 10-Q · filed 2025-08-13 | -$44.49M derived: sum of 3 quarters · filed 2025-08-13 | -$54.21M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$14.39M 10-Q · filed 2025-05-14 | -$26.15M derived: sum of 2 quarters · filed 2025-05-14 | -$35.87M derived: sum of 3 quarters · filed 2025-05-14 | -$44.99M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$21.48M derived: sum of 2 quarters · filed 2025-03-20 | -$30.61M derived: sum of 3 quarters · filed 2025-03-20 | -$37.81M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$9.72M 10-Q · filed 2024-11-12 | -$18.84M derived: sum of 2 quarters · filed 2024-11-12 | -$26.04M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$9.13M 10-Q · filed 2024-08-13 | -$16.33M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$7.20M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |